Rituximab

Rituximab in the glossary for Waldenström's macroglobulinemia

Rituximab is a chimeric monoclonal antibody anti-CD20 antibody

Rituximab is a chimeric monoclonal antibody against the protein CD20, which is primarily found on the surface of immune system B cells. When it binds to this protein, it triggers cell death. Rituximab is primarily used to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia, Wegener's granulomatosis, pemphigus vulgaris, and rheumatoid arthritis. Rituximab is authorized for use in the EU.¹ Rituximab is authorized for use in Australia.²

Glossary overview

References

1.Rituximab SmPC. Available from; https://www.ema.europa.eu/en/documents/product-information/mabthera-epar-product-information_en.pdf. Accessed November 12th, 2021.

2.Australian Public Assessment Report for Rituximab. Available from; https://www.tga.gov.au/auspar/auspar-rituximab-8. Accessed Novemver 12, 2021.

This website contains information for a broad scientific audience and may include information on products or indications that are not licensed, approved, or accessible in your country or region. Prescribing information or other medical information for products may also differ between countries or regions. Please consult the appropriate national or regional regulatory authority for specific information on a product or indication included here.